Practice Test Geeks(RAC) Regulatory Affairs Certification Practice Test
← All RAC Flashcard Decks

Product Development & Registration Flashcards

7 cards from real RAC practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Product Development & Registration flashcards as text

  1. What is the primary regulatory distinction between a drug product's 'indication' and its 'intended use' in labeling?

    Answer: Indication refers to the disease state targeted; intended use encompasses the broader population and clinical setting described in labeling

    An indication specifies the disease or condition the drug treats, while intended use in labeling describes the full clinical context including population, setting, and purpose.

  2. Under the Common Technical Document (CTD) structure, Module 4 contains which type of information?

    Answer: Nonclinical study reports

    Module 4 of the CTD contains nonclinical (pharmacology and toxicology) study reports supporting safety evaluation of the drug.

  3. A company wants to make a manufacturing change to an approved NDA product that has 'substantial potential' to adversely affect drug identity, strength, quality, purity, or potency. What submission is required?

    Answer: Prior Approval Supplement (PAS)

    Changes with substantial potential to affect product quality require a Prior Approval Supplement, which must be approved by FDA before the change is implemented.

  4. Which clinical trial phase is primarily designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a new drug in a small number of healthy volunteers or patients?

    Answer: Phase 1

    Phase 1 trials are first-in-human studies focused on safety, tolerability, PK/PD, and dose range finding in small groups (typically 20–100 subjects).

  5. What is the role of a Reference Listed Drug (RLD) in the ANDA (generic drug) approval process?

    Answer: It serves as the benchmark to which the generic applicant must demonstrate bioequivalence

    The RLD is the approved brand-name drug to which a generic applicant must demonstrate bioequivalence in an ANDA submission.

  6. Under ICH E6(R2) Good Clinical Practice guidelines, what is the sponsor's primary responsibility regarding an Investigational Medicinal Product (IMP)?

    Answer: Ensuring the IMP is manufactured, handled, and stored in accordance with applicable GMP and used in accordance with the approved protocol

    ICH E6(R2) places responsibility on the sponsor for ensuring proper GMP manufacture, appropriate handling/storage, and protocol-compliant use of the IMP.

  7. What triggers the requirement for a Risk Evaluation and Mitigation Strategy (REMS) for an NDA or BLA?

    Answer: FDA determines that a REMS is necessary to ensure the benefits of the drug outweigh its risks given a serious safety concern

    REMS is required when FDA determines that additional risk management beyond labeling is necessary because of a serious safety concern specific to that drug.